AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Innate Pharma

Board/Management Information Feb 12, 2019

1440_iss_2019-02-12_ebb02c9b-0c10-4712-86df-7302957b8a54.pdf

Board/Management Information

Open in Viewer

Opens in native device viewer

INNATE PHARMA ANNOUNCES APPOINTMENT OF LAURE-HÉLÈNE MERCIER TO THE EXECUTIVE BOARD

Appointments of Dr. Mondher Mahjoubi, Chief Executive Officer, and Dr. Yannis Morel, EVP Business Development and Portfolio Strategy, renewed to the Executive Board for three years

Marseille, France, February 12, 2019, 7:00 AM CET

Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 – IPH) today announces that the Supervisory Board of Innate Pharma has strengthened the Company's leadership and corporate governance with the appointment of Laure-Hélène Mercier, Chief Financial Officer, as a member of the Executive Board for a period of three years.

Laure-Hélène Mercier, MSc, M MCLaure

Information about Innate Pharma shares:

ISIN code FR0010331421
Ticker code IPH
LEI 9695002Y8420ZB8HJE29

Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website www.amf-france.org or on Innate Pharma's website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Investors International Media
Innate Pharma Consilium Strategic Communications
Dr. Markus Metzger / Danielle Spangler /
Jérôme Marino
Mary-Jane Elliott / Jessica Hodgson
Tel.: +44 (0)20 3709 5700
Tel.: +33 (0)4 30 30 30 30 [email protected]
[email protected]

French Media

ATCG Press

Solène Moulin Tel.: +33 (0)9 81 87 46 72 [email protected]

Talk to a Data Expert

Have a question? We'll get back to you promptly.